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Abstract
Transcription factor NFKB and the serine/threonine
kinase Akt play critical roles in mammalian cell survival
signaling and have been shown to be activated in
various malignancies including prostate cancer (PCA).
We have developed an analogue of curcumin called 4-
hydroxy-3-methoxybenzoic acid methyl ester (HMBME)
that targets the Akt/NFKB signaling pathway. Here, we
demonstrate the ability of this novel compound to
inhibit the proliferation of human andmouse PCA cells.
HMBME-induced apoptosis in these cells was tested by
using multiple biochemical approaches, in addition to
morphological analysis. Overexpression of constitu-
tively active Akt reversed the HMBME-induced growth
inhibition and apoptosis, illustrating the direct role of
Akt signaling in HMBME-mediated growth inhibition
and apoptosis. Further, investigation of the molecular
events associated with its action in LNCaP cells shows
that: 1) HMBME reduces the level of activated form of
Akt (phosphorylated Akt); and 2) inhibits the Akt kinase
activity. Further, the transcriptional activity of NFKB,
the DNA-binding activity of NFKB, and levels of p65
were all significantly reduced following treatment with
HMBME. Overexpression of constitutively active Akt,
but not the kinase dead mutant of Akt, activated the
basal NFKB transcriptional activity. HMBME treatment
had no influence on this constitutively active Akt-
augmented NFKB transcriptional activity. These data
indicate that HMBME-mediated inhibition of Akt kinase
activity may have a potential in suppressing/decreas-
ing the activity of major survival/antiapoptotic path-
ways. The potential use of HMBME as an agent that
targets survival mechanisms in PCA cells is discussed.
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Introduction
Prostate cancer (PCA) is the most common lethal malig-
nancy in men and is responsible for about 31,000 deaths
annually in the United States [1]. Adenocarcinoma of the
prostate is generally slow-growing; nonetheless, the morbidity
from the disease is high because of urologic impairment and
painful bone metastasis. Because PCA incidence increases
with advancing age, it is expected that this malignancy will
become an increasingly greater problem as worldwide life
expectancy improves. Most PCA patients are diagnosed with
advanced stage of metastatic disease for which there is no
effective therapy available at this time [2–4]. Therefore, there
is a continuous demand for identification and development of
nontoxic agents for the management of PCA. Preventing or
inhibiting the progression of PCA by dietary and medicinal
phytochemicals is currently gaining substantial interest. In
particular, agents that 1) interfere with tumor development by
slowing down disease progression and 2) improve the quality of
life and have exceptional clinical value are gaining ground.
Most plants contain phenolic/polyphenolic antioxidants such as
flavonoids, hydroxy cinnamic acid derivatives, and simple
phenols and phenolic acids [5,6].
Curcumin (diferuloylmethane) is the major active yellow
pigment of the rhizome of the turmeric plant that is widely used
as a food-flavoring agent by Asians. Curcumin has been shown
to have antiproliferative and antioxidant properties in human
tumor cell cultures and to prevent cancer in many animal
models [7–17]. Recently, Perkins et al. [17] showed chemo-
preventive activity of curcumin in a mouse model that is
germane to human colorectal cancer involving Apc mutations.
Thus, the use of curcumin or its related compounds in the diet
can potentially decrease the susceptibility to cancer-causing
agents. This may be one of the reasons for the observed lower
incidence of PCA seen in Asians. Consistent with this idea,
Dorai et al. [18] showed growth inhibition of both androgen-
responsive and androgen-independent PCA cells treated with
curcumin through the induction of apoptosis. Subsequently, the
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same group demonstrated that use of 2% curcumin in the
diet strongly inhibited the growth of LNCaP PCA cells in
athymic nude mice [19]. In contrast, Imaida et al. [20]
reported no chemopreventive effect of curcumin (500 ppm)
against DMAB- or PhIP-induced prostate carcinogenesis.
Although several other factors including organ specificity
could contribute to this lack of chemopreventive effect, it is
very possible that this may be due to low absorption or rapid
metabolism of curcumin in this model.
Curcumin exhibits its antiproliferative activities in cell
culture studies in the range of 10 to 100 AM. However, the
bioavailability of curcumin has been shown to be low in
rodents [21–25]. For example, administration of 1 g/kg body
weight of mouse yielded a plasma level of 0.5 AM (0.06%
absorption). In addition, oral dosing of humans with 4 to 8 g of
curcumin showed plasma levels of about 0.41 to 1.75 AM
(about 0.004–0.008% absorption). Such low plasma levels
may not bring forth the optimal chemopreventive and/or
therapeutic effect. It is also very likely that curcumin is
biotransformed to products that are responsible for, or con-
tribute to, this effect. Although the metabolism of curcumin in
humans is poorly understood, curcumin’s bioavailability may
be poor in humans based on the recent study in colorectal
cancer patients [22–25]. These observations indicate that
the prospective clinical utility of curcumin is seriously limited.
We have synthesized several smaller derivatives of
curcumin that retain its polar functionality [26]. These ana-
logues lack the dieneone structure of curcumin and, hence,
they are not subjected to the type of reductive metabolism
documented with curcumin in vivo. These derivatives are
more soluble than curcumin while potentially retaining cur-
cumin’s favorable biologic activities. After testing these
compounds for their potential to inhibit growth of PCA cells,
we determined 4-hydroxy-3-methoxy benzoic acid methyl
ester (HMBME) to be a lead compound for further studies.
The structure of HMBME is shown below (Figure 1). In this
study, we investigated the potential of HMBME to inhibit the
growth of various PCA cells and the underlying mechanisms
involved. In addition, we show that HMBME induces apop-
tosis in LNCaP cells by targeting the Akt/NFnB survival
signaling pathway.
Materials and Methods
Synthesis of 4-Hydroxy-3-Methoxybenzoic Acid Methyl
Ester (HMBME)
Two grams of 4-hydroxy-3-methoxybenzoic acid (Aldrich,
Milwaukee, WI) was dissolved in 60 ml of dry methanol. After
adding 5 mg of p-toluenesulfonic acid monohydrate (Aldrich),
the reaction was refluxed for 24 hours. Following evaporation
of the solvent in vacuo, the residue was purified by flash silica
gel chromatography using hexane/ethyl acetate (70:30) as
eluting solvent. The purified fractions were identified by thin
layer chromatography on silica gel. These fractions were
combined and the solvent was evaporated in vacuo to give
HMBME. The purity was checked by gas chromatography
mass spectroscopy, which showed major peaks at m/z 182
(90) and 151 (100). Proton NMR in CDCl3: d 3.804 (s, 3H);
d 3.835 (s, 3H); d 6.187 (broad s, 1H); d 6.844 and 6.865
(d, 1H); d 7.459 and 7.463 (d, 1H); and d 7.539, 7.544, 7.560,
and 7.564 (q, 1H).
Cell Lines
Human PCA cell lines including androgen-responsive
(LNCaP) and androgen-independent (DU145) were grown
as described earlier [27]. In addition, a human benign
prostatic hyperplasia cell line (BPH-1) was obtained from
Dr. Gary Millers’ laboratory (University of Colorado Health
Sciences Center, Denver, CO). BPH-1 is an immortalized
cell line derived from primary prostatic epithelial cells using
SV40 lager T antigen [28]. Due to expression of SV 40T
antigen (that inactivates p53 and Rb), this cell line is suscep-
tible to genetic alterations during carcinogenesis process
and can be considered tumorigenic. TRAMP cell lines
obtained from Dr. Norman Greenberg (Baylor College of
Medicine, Houston, TX) were grown as described earlier
[29]. Nontumorigenic fibroblast cell line GM0637 was
obtained from Dr. David Mitchell (The University of Texas
M.D. Anderson Cancer Center, Smithville, TX) and was
grown as described elsewhere.
Cell Viability and Proliferation Assay
Actively growing cells (LNCaP, DU145, GM-0637, BPH-1,
and TRAMP cell lines) were plated in 96-well plates at a
density of 4 103 cells/well in five replicates. After 24 hours
in a 37jC incubator with 5% CO2, cells were treated with
the indicated concentration of HMBME. Control cells
received only the vehicle (DMSO). Cell viability was deter-
mined by the trypan blue exclusion assay. Cell growth was
monitored every 24 hours using the CellTiter96 Aqueous
One solution assay containing a tetrazolium compound
(Promega, Madison, WI).
Colony Formation Assay
Logarithmically growing cells (LNCaP) were trypsinized
and plated at a density of 13,000 cells/ml in 0.5% agarose
plates in triplicate. Plates were prepared fresh by adding
0.5 g of agar (FMC 50102) to 100 ml of complete growth
media and by incubating in a water bath at 44jC. Two
milliliters of this agarose was evenly layered in six-wellFigure 1. Structure of HMBME.
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plates and allowed to solidify for 30 minutes. Two milliliters
of complete media containing 0.5% agar was added to
40,000 cells. After mixing, 1 ml of media containing cells
was poured on top of the 0.5% media in the six-well plate. A
plate containing no cells was used as a negative control.
After 14 days, cells were stained with 0.02% p-iodonitrote-
trazolium. After 5 hours, the colonies that stained dark pink
were counted in 10 different fields from each well.
Flow Cytometric Analysis
Logarithmically growing (LNCaP) cells were plated at a
density of 1 105 in 60-mm dishes as described above.
Cells at 70% to 80% confluency were treated at time 0 with
25 AM HMBME or solvent control for 24 hours. Cells were
harvested by trypsinization and the cell pellet was resus-
pended in 1 ml of Krishan stain containing 1.1 mg/ml sodium
citrate, 46 Ag/ml propidium iodide, 0.01% NP40, and 10 Ag/
ml RNase [27]. Flow cytometric analysis was preformed at
the Flow Cytometry core facility of the University of Colorado
Comprehensive Cancer Center (Denver, CO) using a
Coulter XL flow cytometer (Beckman-Coulter, Hialeah, FL).
Data were analyzed using Modfit LT from Verity Software
House (Topsham, Maine).
Detection of Apoptosis
Logarithmically growing cells (LNCaP) were plated at a
density of 1 105 in 60-mm dishes as described above. At
70% to 80% confluence, cells were treated with HMBME
(25 AM for 24 hours). Following incubation, both the adherent
and floating cells were collected by trypsinization for detec-
tion of apoptosis usingmorphologic analysis, FITC–Annexin,
and acridine orange staining [30].
FITC–Annexin
During the initial stages of apoptosis, cells lose their
phospholipid membrane asymmetry and phosphotidylserine
(PS) is exposed to the cell surface. This can be monitored by
using Annexin V, which is a phospholipid-binding protein with
high affinity for PS. Because translocation of PS occurs not
only during apoptosis but also during necrosis, PI is used to
distinguish between late and early stages of apoptosis. We
used the Annexin V–FITC kit (Medical and Biological Labo-
ratories, Watertown, MA) to quantify apoptosis in LNCaP
cells treated with HMBME (25 AM for 24 hours) using flow
cytometry as per manufacturer’s recommendations.
Acridine Orange/Ethidium Bromide Staining
Briefly, 25 Al of dye mixture (acridine orange and ethidium
bromide, 100 Ag each in 1 ml) was mixed with 25 Al of cell
suspension and was examined under a fluorescent micro-
scopewith a blue filter. Viable cells (green) and apoptotic cells
containing fragmented nuclei (red) were counted and the
percentage of apoptotic cells was then calculated. Cells were
counted in at least five different fields in triplicate samples.
Transfections and Transient Expression Assays
Transient transfections were performed in LNCaP cells
using a lipofectin reagent (Invitrogen, Carlsbad, CA) accord-
ing to the manufacturer’s recommendations. Briefly, pNFnB
reporter plasmid (1 Ag/well) and pRL-TK plasmid (50 ng/well;
renilla luciferase for normalization) were incubated with the
lipofectin reagent for 30 minutes at room temperature. The
DNA–lipofectin mixture was then added to the cells and
incubated for 48 hours. Forty-eight hours after transfection,
cells were treated with HMBME (25 AM) for 2 hours. Follow-
ing HMBME treatment, cells were collected and lysed in
passive lysis buffer (PLB) as per manufacturer’s recommen-
dations (Promega). Cell lysate was cleared from debris by
centrifuging at 10,000 rpm for 5 minutes at 4jC. Luciferase
activity was assayed using Dual Luciferase Reporter Assay
System (Promega) in duplicate samples containing equal
amounts of protein. The assay mixture contained 20 Al of cell
lysate and 50 Al of firefly luciferase measuring buffer (LARII).
Firefly luciferase activity was measured on a Genios Tecan
luminometer (Phenix Research Products, Hayward, CA).
After measuring the firefly luciferase activity, the reaction
mixture was added to 50 Al of renilla luciferase measuring
buffer (Stop and Glow) and renilla luciferase activity was
measured. Renilla luciferase activity was used to normalize
the transfection efficiency. Results are expressed as the ratio
of firefly luciferase/renilla luciferase at equal amounts of
protein. For cotransfection experiments, the super repressor
InBa mutant expression vector (1 Ag/well), constitutively
active Akt (1 Ag/well), and kinase dead mutant of Akt (1 Ag/
well) were included along with the pNFnB reporter plasmid.
To determine the effect of overexpression of Akt on
HMBME-induced growth inhibition and apoptosis, subcon-
fluent LNCaP cells were transfected with either pCMVMyr-
Akt (an activated form of Akt with the Src myristoylation
signal fused in-frame to the c-Akt coding sequence) or
control vector (pCMV) using Lipofectamin (Invitrogen) as
described above. Forty-eight hours following transfection,
cells were treated either with 25 AM HMBME or solvent
control. Both floating and adherent cells were collected
after 2 hours of treatment and assessed for 1) morphologic
alterations; 2) cell viability by trypan blue exclusion assay;
and 3) apoptosis by acridine orange//ethidium bromide
staining [30].
Electrophoretic Mobility Shift Assays (EMSAs)
Gel shift assays were done as described elsewhere [31–
33]. Double-stranded NFnB oligonucleotide was end-labeled
with g-p32-ATP using T4 polynucleotide kinase. Nuclear
extracts were incubated with the radiolabled probe in binding
buffer (containing 4 mM Tris–HCl, 12 mM Hepes, pH 7.9,
60 mM KCl, 0.5 mM EDTA, 1 mM DTT, and 12% glycerol) for
20 minutes at room temperature in a final volume of 20 Al.
After incubation, samples were fractionated on a 4% poly-
acrylamide gel in 0.25 TBE at 4jC. Following electro-
phoresis, the gel was dried and autoradiographed. For
competition studies, the radiolabled probe was mixed with
100-fold molar excess of unlabelled double-stranded syn-
thetic NFnB oligonucleotide (homologous competition) and
Sp1 (for heterologous competition) for 20 minutes prior to
the addition of extracts. For gel supershift experiments, the
nuclear extracts were preincubated for 30 minutes with
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either normal rabbit serum (NRS) or p65 or p50 antibody and
used in EMSA as described [33].
Preparation of Cell Extracts
Actively growing LNCaP Cells were treated with 25 AM
HMBME for indicated time periods (15 minutes, 30 minutes,
60minutes, 2 hours, and 24 hours). Following treatment, cells
were lysed in a buffer containing (50 mM Tris–HCl, pH 7.4,
150mMNaCl, 0.5% NP40, 50 mMNaF, 1 mMNa VO4, 1 mM
phenylmethylsulfonyl fluoride, 25 Ag/ml leupeptin, 25 Ag/ml
aprotinin, 25 Ag/ml pepstatin, and 1 mM DTT). After passing
the lysate through a 25-gauge needle, cell debris was
removed by centrifugation at 12,000 rpm for 30 min.
Nuclear Extracts
Nuclear extracts were prepared according to the method
of Dignam and protein content of the extracts was deter-
mined by the method of Bradford as described [32].
Western Blotting
Equal amounts of extracts were fractionated on a 10%
SDS polyacrylamide gel. Following electrophoresis, proteins
were electrophoretically transferred to a nitrocellulose mem-
brane. The blotted membrane was blocked with 5% nonfat
dried milk in Tris-buffered saline containing 0.1% Tween 20
(blocking solution), and incubated with indicated polyclonal
antibodies (Santa Cruz Biotechnology, Santa Cruz, CA; Cell
Signaling Technology, Beverly, MA) followed by incubation
with horseradish peroxidase–conjugated antirabbit IgG anti-
body (Sigma) in blocking solution. Bound antibody was
detected by enhanced chemiluminescence using Supersig-
nal West Pico Chemiluminescent Substrate, following the
manufacturer’s directions (Pierce, Rockford, IL). All the blots
were stripped and reprobed with h-actin to ensure equal
loading of protein.
Akt Kinase Assay
Endogenous Akt kinase was measured in the extracts
from control and HMBME-treated LNCaP cells using Akt
kinase assay kit (Cell Signaling Technology). Briefly, cell
extracts were incubated with immobilized Akt monoclonal
antibody overnight. Following extensivewashes, kinase reac-
tion was performed in the presence of 200 AM cold ATP and
GSK-3 substrate. Phosphorylation of GSK-3 was measured
by Western blotting using phospho-GSK-3 antibody.
   
     
Figure 2. (A) Effect of HMBME on proliferation of androgen-responsive
(LNCaP), androgen-independent (DU145), benign prostatic epithelial (BPH-1),
and nontumorigenic fibroblasts (GM0637). Cells were plated in 96-well
plates as described in Materials and Methods section and treated with
indicated concentrations of either HMBME or solvent control. Cell
proliferation was measured by CellTiter96 Aqueous One solution assay at
a 72-hour time point by determining the absorbance at 570 nm using
SpectraMaxPlus plate reader (Molecular Devices, Sunnyvale, CA). The data
shown here are an average FSD of five replicate wells and are
representative of four independent experiments. (B) Effect of HMBME on
the proliferation of TRAMP cell lines. The experimental procedure was the
same as described in legends for (A). (C) Effect of HMBME on colony-
forming ability of LNCaP cells. Cells were plated in triplicate in 35-mm dishes
on 0.5% agarose-containing media as described in Materials and Methods
section. Following 14-day incubation, cells were stained with 0.5 ml of 0.02%
p-iodonitrotetrazolium and colonies were counted in 10 different fields from
each plate. The results are expressed as meanFSD of five replicate wells
and are representative of two independent experiments.
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Results and Discussion
HMBME Inhibits the Growth of Human and Mouse PCA
Cells without Influencing the Growth of Nontumorigenic
Fibroblasts
The effect of HMBME was tested on the growth of benign
prostate hyperplasia (BPH-1), androgen-sensitive human
PCA cells (LNCaP), and androgen-independent (DU145)
human PCA cells. Trypan blue exclusion assay and Cell-
Titer96 Aqueous One solution assay containing a tetrazolium
compound (Promega) were used to determine the cell pro-
liferation, as described previously [27]. The assay is based
on the principle that actively growing cells generate reducing
equivalents, such as NADH, that are necessary for the cells
to reduce the tetrazolium compound to a formazan product.
This was detected by measuring the absorbance at 570 nm
using a plate reader. An increase in the conversion of the
MTS tetrazolium compound to the colored formazan product
(indicated by increased absorbance) provides a relative
measure of viable cell number, whereas a decrease provides
a relative measure of cell death over a period of time. As
shown in Figure 2A, incubation of cells (LNCaP, DU145, or
BPH-1) with HMBME showed a dose-dependent decrease in
the cell proliferation. This is consistent with the data obtained
using trypan blue exclusion assay (data not shown). In
addition, we tested the effect of HMBME on mouse PCA cell
lines. These prostate tumor cell lines designated as TRAMP
C2 and TRAMP C3 are derived from different stages of PCA
progression from transgenic adenocarcinoma of mouse
prostate (TRAMP) mice and express androgen receptors
(ARs). As shown in Figure 2B, HMBME was effective in
inhibiting the growth of both cell lines.
Further, we compared the effect of HMBME on the
growth of GM0637, a nontumorigenic fibroblast cell line.
As shown in Figure 2A, 25 AM HMBME (the concentration
that caused approximately 40% growth inhibition in PCA cell
lines) did not affect the growth of these cells. In contrast,
25 AM curcumin (parent compound) inhibited the growth of
GM0637 cells (data not shown). In order to produce com-
parable inhibition in these cells, a concentration of more
than 50 AM HMBME was necessary. Because GM0637 cells
are not prostatic in origin, we cannot draw any conclusions
regarding the specificity of HMBME towards tumor cells;
however, these results indicate that HMBME inhibits prolif-
eration of tumor cells more efficiently compared to non-
tumorigenic fibroblast cells.
HMBME Inhibits the Anchorage-Independent Growth of
LNCaP Cells
We tested the effect of HMBME on the anchorage-
independent growth of LNCaP cells as assayed by their abil-
ity to grow as colonies in soft agar. As shown in Figure 2C,
there was a dose-dependent decrease in the colony-form-
ing ability of LNCaP cells following exposure to HMBME.
Inclusion of 25 AM HMBME in the soft agar assay inhibited
colony formation by more than 50%. These data indicate
that anchorage-independent growth of LNCaP cells on soft
agar was significantly inhibited by HMBME that is consis-
tent with the above cell proliferation data. In contrast,
untreated cells continued to proliferate during the course of
the experiment.
HMBME Induces G1-Specific Cell Cycle Block and Apoptosis
in LNCaP Cells
To examine the effect of HMBME on cell proliferation, we
performed cell cycle analysis in which cellular DNA content
was measured in propidium iodide–stained cells by flow
cytometry. As shown in Figure 3A, incubation of LNCaP cells
with 25 AM HMBME for 24 hours blocked cells in G1-phase
with concomitant decrease in S-phase population of cells.
HMBME treatment had no significant effect on the population
of cells in G2/M-phase. Figure 3A is a graph that shows an
average of three independent experiments and Figure 3B is
a representative histogram of flow analysis.
Figure 3. Effect of HMBME on cell cycle distribution in LNCaP cells. LNCaP
cells were treated with either DMSO alone or with 25 lMHMBME for 24 hours
as described in Materials and Methods section. Following treatment, cells
were harvested, washed with PBS, and then resuspended in 1 ml of Krishan
stain containing 1.1 mg/ml sodium citrate, 46 lg/ml propidium iodide, 0.01% of
NP40, and 10 lg/ml RNase. Data were analyzed using Modfit LT (panel B).
Alterations in the distribution of cells in different phases are also shown as a
graph (panel A). This is an averageFSD of three independent experiments.
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HMBME Promotes Apoptosis in LNCaP Cells
Actively growing LNCaP cells were treated either with
DMSO (solvent control) alone or 25 AM HMBME for different
time points (24, 48, and 72 hours). Cells were examined
microscopically every 24 hours for morphologic changes
associated with treatment. As shown in Figure 4A, signifi-
cant changes in the morphology including blebbing, con-
densation of the nuclear material, rounding of cells, and
detachment from the dishes were seen in cells treated with
HMBME. In addition, we observed cells with granular
appearance. All of these are characteristic features of
apoptosis. Vehicle-treated cells remain unchanged. Photo-
micrographs shown here were taken by phase contrast
microscopy at  40 magnification following 24 hours of
treatment. These data indicate that the suppression of cell
growth in LNCaP cells is associated with morphologic alter-
ations consistent with induction of apoptosis. We confirmed
the induction of apoptosis using additional independent
approaches, as discussed in Materials and Methods sec-
tion. The two-dimensional plots shown in Figure 4B display
green fluorescence (Annexin binding) on the X-axis and
orange fluorescence (PI uptake) on the Y-axis. Cells in the
upper left quadrant with low Annexin and high PI staining
represent necrotic cells; cells in the upper right quadrant
with high Annexin and high PI staining represent late
apoptotic cells; cells in the lower left quadrant with low
Annexin and low PI staining represent viable cells; and cells
in the lower right quadrant with high Annexin and low
PI staining represent early apoptotic cells. As shown in
Figure 4B, untreated cells show less than 10% spontaneous
apoptosis; however, incubation with HMBME (for 24 hours)
induced apoptosis in about 30% of the cells. This is also
consistent with results obtained using acridine orange/ethi-
dium bromide staining that showed approximately 30% of
cells undergoing apoptosis (Figure 4C). The same concen-
tration of HMBME inhibited the colony-forming ability of
LNCaP cells by more than 50% (Figure 2C). These differ-
ences could be due to sensitivity of the techniques. These
data using different biochemical approaches clearly demon-
strate that HMBME inhibits the growth of LNCaP cells
through induction of apoptosis.
Modulation of Cell Survival Signaling Components Following
HMBME Treatment
The observed decreased cell proliferation could be due
to modulation of cell survival signaling pathway. It has been
well established that the antiapoptotic kinase Akt and
antiapoptotic factor NFnB play a critical role in the cell
survival signaling pathway in a variety of cancers including
PCA [34–40]. Akt is a well-characterized serine/threonine
kinase that promotes cell survival and is activated in
response to many different growth factors. Activation of
Akt signaling pathway promotes cell survival by inhibiting
apoptosis through phosphorylation of the proapoptotic pro-
tein BAD and other proteins. In a recent study, Malik et al.
[41] have shown an increased expression of phospho-Akt in
human PCA specimens indicating the activation of cell
survival signaling pathways and suppression of apoptosis.
This result is consistent with the observation that PTEN, a
negative regulator of Akt, is altered and inactive in many
types of cancers including PCA [42,43]. PTEN is also the
most widely mutated tumor suppressor gene in PCA and
may also contribute to the acquisition of the metastatic
phenotype [44]. In addition, activated Akt can also exert
its antiapoptotic effects through regulation of transcription
factors such as NFnB [45,46]. The transcription factor
NFnB has been shown to play an important role in coordi-
nating the control of apoptotic cell death, which either
promotes or inhibits apoptosis depending on the cell type
and the apoptotic stimuli [34,35]. Overexpression of NFnB
has been shown to be associated with various malignancies
including PCA. Activation of NFnB has been shown to be
associated with decreased levels of apoptosis in vitro and
mice lacking p65 exhibit increased levels of apoptosis [47–
49]. Similarly, although staining was heterogeneous, tumor
samples obtained from radical prostatectomy patients
showed activation of NFnB [49]. Thus, targeting Akt/NFnB
signaling is a potential strategy for suppression of cancer
cell survival as a means of cancer management. With this
background, we have hypothesized that HMBME may
induce apoptosis through inhibition of Akt/NFnB–mediated
cell survival signaling pathway.
Constitutive Expression of Akt Protects LNCaP Cells from
HMBME-Induced Growth Inhibition and Apoptosis
To show that HMBME-induced growth inhibition was
mediated through the inhibition of Akt activation, transient
transfections were performed using either pCMVMyrAkt or
control vector (pCMV), as described in Materials and
Methods section. As shown in Figure 5A, HMBME treat-
ment inhibited the growth of LNCaP cells transfected with
control vector that shows HMBME’s growth-inhibitory effect
and is consistent with the above cell proliferation data. In
contrast, overexpression of constitutively active Akt pro-
tected LNCaP cells from the growth-inhibitory activity of
HMBME. Although these data demonstrate a critical role
for Akt signaling in HMBME-induced growth inhibition, it
does not prove the involvement of Akt signaling in
HMBME-induced apoptosis.
To show the involvement of Akt activation in HMBME-
induced apoptosis, we measured apoptosis in LNCaP cells
transfected with either pCMVMyrAkt or control vector
(pCMV), as described in Materials and Methods section.
Induction of apoptosis was assessed both by morphologic
analyses as well as acridine orange/ethidium bromide stain-
ing. Microscopic observations of vector-transfected cells
show characteristic features of apoptosis unlike MyrAkt-
transfected cells following treatment with HMBME (data not
shown). As shown in Figure 5B, between 20% and 25% of
LNCaP cells transfected with control vector underwent apop-
tosis following HMBME treatment (after normalizing for
spontaneous apoptosis). In contrast, overexpression of con-
stitutively active Akt protected LNCaP cells from undergoing
apoptosis following treatment with HMBME. These data
demonstrate that HMBME-induced apoptosis is mediated
through inhibition of Akt activation.
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Figure 4. (A) Morphologic alterations of LNCaP cells following HMBME treatment. LNCaP cells were treated with either DMSO or with different concentrations of
HMBME (5, 25, and 50 lM) for 24 hours. Photomicrographs of these cells were taken by phase contrast microscopy using a Nikon Microscope with a digital camera
system Coolpix 995 at a magnification of 20 (Nikon, Tokyo, Japan). The picture shown here shows cells treated with 25 lM HMBME for 24 hours. Arrows indicate
apoptotic cells. (B and C) Induction of apoptosis following treatment with HMBME. Cells were treated with HMBME (25 lM for 24 hours) and induction of apoptosis
was detected by FITC–Annexin staining through flow cytometry and acridine/orange staining. Both the adherent and floating cells were collected by trypsinization
for quantification of apoptosis as described in Materials and Methods section. A representative graph of FITC–Annexin is shown (B). Data shown for acridine
orange/ethidium bromide staining are averageFSD of two independent experiments conducted in triplicate. Cells were counted in four different fields for each
sample (panel C).
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HMBME Reduces NFnB Transcriptional Activity,
DNA-Binding Activity, and Levels of p65
NFnB is an important transcription factor that controls
transcription of a large number of genes involved in various
cell functions including apoptosis. Mammalian cells contain
different subunits of NFnB including p65 (65-kDa DNA-
binding subunit and an associated 50-kDa protein referred
to as p50 [48]). We examined the role of NFnB in mediating
Figure 5. (A) Overexpression of constitutively active Akt protects LNCaP cells from HMBME-induced cell growth inhibition. Subconfluent LNCaP cells were
transfected with either pCMVMyrAkt (an activated form of Akt with the Src myristoylation signal fused in-frame to the c-Akt coding sequence) or control vector
(pCMV) using Lipofectamin (Invitrogen) in triplicate dishes. Forty-eight hours following transfection, cells were treated either with 25 lM HMBME or solvent control.
Both floating and adherent cells were collected after 2 hours of treatment and assessed for cell viability by trypan blue exclusion assay. The data shown here are
averageFSD of three independent experiments. (B) Overexpression of constitutively active Akt protects LNCaP cells from undergoing apoptosis following
treatment with HMBME. Experiments were conducted essentially as described in (A). Both floating and adherent cells were collected after 2 hours of treatment and
assessed for apoptosis as described in Materials and Methods section. The data shown here are averageFSD of two independent transfections. (C) Influence of
HMBME on transcriptional activity of the NFjB promoter. Transient transfections were performed with pNFjB reporter plasmid (1 lg/well) and pRL-TK plasmid
(50 ng/well; renilla luciferase for normalization) as described in Materials and Methods section using Lipofectin reagent. Forty-eight hours after transfection, cells
were treated with HMBME (25 lM) for 2 hours. Firefly and renilla luciferase activity was measured in the extracts prepared from these using Dual Luciferase
Reporter Assay System (Promega) in duplicate samples containing equal amounts of protein. Renilla luciferase activity was used to normalize for transfection
efficiency. Results are expressed as the ratio of firefly luciferase/renilla luciferase at equal amounts of protein. The data shown here are a representative experiment
that was performed for four times with two different preparations of plasmid. For cotransfection experiments, indicated expression plasmids (1 lg/well) were
included along with the pNFjB reporter plasmid. The data shown here are a representative experiment that was performed for four times with two different
preparations of plasmid. (D) EMSA of nuclear extracts prepared from control and HMBME-treated cells. Nuclear extract (5 lg) was incubated with approximately 0.2
ng of NFjB consensus oligonucleotide as radiolabeled probe as described in Materials and Methods section and the DNA–protein complexes were resolved on a
4% nondenaturing gel by electrophoresis and subject to autoradiography. (E) Identification of protein components of NFjB DNA-binding activity. Nuclear extracts
prepared from LNCaP cells were preincubated with p65, p50, or NRS for 30 minutes on ice. These extracts were used in EMSA with NFkB probe as described in
legends for (C). Supershifted complex is indicated as p65/p50 complex and NS indicates nonspecific band. (F) Western blot analysis of whole cell extracts from
LNCaP cells following treatment with HMBME. Twenty-five micrograms of extract from control or HMBME-treated cells was fractionated on 10% SDS-PAGE and
transferred to a nitrocellulose membrane. After blocking, the membrane was incubated for 2 or 3 hours with the antibody p65. This was followed by incubation with
secondary horseradish peroxidase–conjugated antirabbit IgG antibody (Sigma) in blocking solution. Bound antibody was detected by Supersignal West Pico
Chemiluminescent Substrate, following the manufacturer’s directions (Pierce). The blot shown here is a representative blot of three independent experiments.
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HMBME-induced apoptosis using transient transfection
expression assays using NFnB luciferase reporter vector
containing four tandem copies of NFnB consensus
sequence (Clontech Laboratories, Palo Alto, CA) and NFnB
B DNA-binding activity in nuclear extracts prepared from
cells treated with HMBME. As shown in Figure 5C, treat-
ment with HMBME (25 AM for 2 hours) reduced the tran-
scriptional activity of the NFnB promoter by about 50%.
Under similar experimental conditions, HMBME did not
affect the promoter activity of the vector alone. In addition,
cotransfections performed with mutant InBa super
repressor (containing mutated serine residues at 32 and
36) blocked this activation of NFnB promoter activity that is
consistent with previous reports (data not shown and Ref.
[50]). These data indicate that NFnB/InBa signaling has a
role in mediating HMBME-mediated reduction in the tran-
scriptional activity of NFnB in LNCaP cells.
We tested the ability of nuclear extracts prepared from
LNCaP cells treated with HMBME to bind the NFnB oligo-
nucleotide in EMSA. As shown in the Figure 5D, extracts
prepared from untreated cells showed one major complex.
This complex was abolished with an excess (100-fold
molar) of unlabeled consensus NFnB but not with Sp1
oligonucleotide indicating the specificity of the interaction
(data not shown). Extracts prepared from HMBME-treated
cells showed a time-dependent decrease in the NFnB DNA-
binding activity that was totally abolished by 24 hours. This
correlates with the observed decrease in the transcriptional
activity of the NFnB promoter following HMBME treatment
(Figure 5C).
We wanted to establish the identity of the proteins in the
observed DNA–protein complex formed with NFnB oligonu-
cleotide in this experiment. Nuclear extracts prepared from
LNCaP cells were preincubated with p65 or p50 antibodies
and then analyzed by EMSA. As shown in Figure 5E, the
bound complex was clearly supershifted in the presence of
p65 antibody and partially supershifted in the presence of p50
antibody. This shows that the bound complex consists of both
p65 and p50. Preincubation of the nuclear extracts with NRS
had no effect on the DNA–protein interaction. We have also
performed Western blot analysis using p65 in the extracts
prepared from LNCaP cells treated with HMBME for different
time points (30 minutes, 60 minutes, 2 hours, and 24 hours).
As shown in Figure 5F, the levels of p65 showed time-
dependent decrease with exposure to HMBME. These blots
were stripped and reprobed with h-actin to ensure equal
loading of protein (data not shown). These results are con-
sistent with the observed decrease in NFnB transcriptional
activity and DNA-binding activity. These results showing the
inhibition of NFnB signaling are consistent with published
reports with curcumin, which is a parent compound for
HMBME [51,52]. These data clearly indicate that interference
with NFnB signaling pathway with HMBME could contribute
to the observed antiproliferative activity with consequent
induction of apoptosis.
NFnB usually resides in the cytoplasm in association with
the inhibitory protein, InB. Degradation of InB in a proteo-
some-dependent signaling pathway leads to translocation of
NFnB to the nucleus with subsequent activation of NFnB-
dependent signaling pathway. Degradation of InB occurs
following its phosphorylation on two serine residues and
subsequent ubiquitination. Although the InB kinase (IKK)
complex consisting of IKKa, IKKh, and other regulatory
proteins has been shown to mediate the phosphorylation of
InB, phosphorylation and activation of IKK by Akt also
promote InB degradation, allowing NFnB to activate the
transcription of antiapoptotic genes [45,46]. Such activation
of NFnB by Akt would be expected to decrease the likelihood
of cell death. The data presented above illustrate that
HMBME may induce apoptosis in LNCaP cells through
inhibition of NFnB activity. Even when NFnB activity is
blocked, other signaling pathways that act independent of
NFnB may be active and block apoptosis. For example, as
discussed above, Akt can inhibit apoptosis through phos-
phorylation of proapoptotic proteins such as BAD and other
proteins. Hence, inhibition of activation of both Akt and NFnB
by a single agent such as HMBME will have dual advantage.
To investigate the role of Akt in mediating HMBME-
induced apoptosis through NFnB, we measured the NFnB
transcriptional activity in the presence and absence of con-
stitutively active Akt. As shown in Figure 6A, overexpression
of myristylated version of Akt (targeted to the plasma mem-
brane and is constitutively active) in LNCaP cells, along with
NFnB luciferase reporter, led to a fivefold increase in NFnB
promoter activity over that obtained with empty vector. This
indicates that Akt specifically influences NFnB induction.
Subsequent experiments using an inactivating mutation of
the kinase domain prevented Akt from potentiating NFnB-
dependent transcription that is consistent with earlier reports
[53]. However, HMBME treatment did not affect the Akt-
mediated induction of NFnB transcriptional activity in LNCaP
cells. This is also consistent with our data showing that
overexpression of Akt protects cells from undergoing apop-
tosis (Figure 5B). We have also measured the ability of
extracts prepared from these transfected cells to determine
if Akt-mediated effects involve alterations in the NFnB DNA-
binding activity. As shown in Figure 6B, extracts prepared
from cells transfected with NFnB reporter plasmid showed
DNA-binding activity that was reduced following treatment
with HMBME (25 AM for 2 hours). This indicates that the
observed reduction in the transcriptional activity (Figure 5C)
is due to reduced DNA-binding activity. Extracts prepared
from Akt-transfected cells showed a complex that is not
altered following treatment with HMBME that is also consis-
tent with the above transfection data. Although the over-
expression of Akt activated NFnB promoter activity, we did
not observe enhanced DNA-binding activity in extracts from
Akt-transfected cells. Whereas it is most likely that Akt may
not be influencing the NFnB activity through its DNA-binding
activity, we do not rule out that the observed effect is due to
low transfection efficiency.
The possibility that HMBME interferes with the Akt kinase
activity to affect Akt/NFnB cell survival signaling pathwaywas
investigated. As shown in Figure 6C (panel A), the extracts
prepared from untreated LNCaP cells showed Akt kinase
activity. However, treatment with HMBME (25 AM) led to
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undetectable levels of Akt kinase activity. These data indicate
that higher levels of Akt kinase activity in LNCaP cells may
protect cells from undergoing apoptosis. Inhibition of Akt
kinase activity by HMBME activates the apoptotic process.
It is noteworthy to mention that Akt has been shown to
phosphorylate IKK-a at threonine residue 23 [45]. Taken
together, these results show that Akt augmentation of NFnB
activity requires Akt kinase activity. The data illustrating the
protection from HMBME-induced apoptosis through overex-
pression of constitutively active Akt further suggest that
increased kinase activity is effective in blocking HMBME-
induced apoptosis. Extracts prepared from untreated LNCaP
cells showed higher levels of p-Akt that is consistent with
published reports (Figure 6C, panel B) [41–44]. However,
treatment with HMBME (25 AM) showed a reduction in the
levels of p-Akt that was completely abolished by 2 hours of
incubation. These data clearly indicate that inhibition of Akt
kinase activation may be the underlying mechanism respon-
sible for the apoptotic effects of HMBME, although we have
not established a functional link among HMBME-induced
decrease in Akt kinase activity, NFnB activity, and increase
in apoptosis. Our data suggest that it may be possible that
inhibition of Akt kinase activity by HMBME activates the
apoptotic process through inactivation of NFnB signaling.
Such functional studies are in progress to determine the
cause-and-effect relationship between Akt and NFnB during
HMBME-inducedapoptosis. It has been shown that theCox-2
inhibitor, celecoxib, inhibits the growth of PCA cells through
induction of apoptosis via a mechanism involving Akt signal-
ing [54]. Although HMBME inhibited the growth of both
androgen-responsive and androgen-independent cells that
differ in the status of PTEN, it is not known if a similar
mechanism as reported for LNCaP cells also operates in
androgen-independent cells. Such studies are currently in
progress in our laboratory.
Conclusions
Epidemiologic studies show marked geographic differences
in the incidence of PCA, with men from Asian cultures having
a lower occurrence of PCA than men from western countries.
The apparent protection against PCA in Asian males may be
due to various genetic and environmental factors because
offspring from men who have moved from Asian to western
countries experience an increased incidence of this disease
similar to that of their new locales. Although PCA is initially
dependent on androgens for growth and is thus responsive
to androgen ablation, progression to androgen-insensitive
state generally ensues. When this occurs, the progression is
poor because no systemic therapy is effective. Therefore,
there is an urgent need for targeted nonhormonal treatment
that inhibits prostatic cancer cells.
Figure 6. (A) Akt activates NFjB promoter activity. Cotransfection experiments were performed essentially as described above for Figure 5B with 1 lg/well of the
indicated expression plasmids (pCMVMyrAkt, an activated form of Akt with the Src myristoylation signal fused in-frame to the c-Akt coding sequence; dn Akt,
construct expressing inactive Akt due to mutation in the kinase domain; or control vector, pCDNA-3, along with the pNFjB reporter plasmid). Luciferase activity
was determined as described above for Figure 5C. (B) EMSA using transfected extracts. Cell extracts prepared from the transfected cells were used in gel shift
experiments as described in Figure 5D. ‘‘C’’ indicates control extract and ‘‘T’’ indicates treated extract (25 lM HMBME for 2 hours). ‘‘F’’ denotes free probe line
without the protein extract. (C) Akt kinase activity and levels of p-Akt following treatment with HMBME. Actively growing LNCaP cells were treated with HMBME
(25 lM) for 24 hours or for different time points as described in Materials and Methods section. Endogenous Akt was immunoprecipitated using an Akt
monoclonal antibody. Following extensive washes, kinase reaction was performed in the presence of 200 lM cold ATP and GSK-3 substrate. Phosphorylation of
GSK-3 was measured by Western blotting using an antiphospho-GSK-3 antibody. Western blotting using pAkt was performed essentially as described in legends
for Figure 5F.
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Signaling pathways activated by growth factor receptors
play an important role in the development of a neoplastic
phenotype. As such, they represent excellent targets for
novel antineoplastic drug development. The Akt pathway
can be activated by various growth factors and plays a very
important role in promoting growth and blocking apoptosis in
various cancer models including PCA. Activated Akt can
suppress apoptosis by mediating the phosphorylation of
downstream effectors such as Bad and procaspase-9, indi-
rectly through regulation of transcription factors such as
NFnB. Thus, it may be a potentially more effective strategy
to block a critical signal transduction pathway such as Akt
that is common to multiple downstream events. The data
presented in this report suggest that targeting Akt/NFnB
signaling is a potential new strategy for suppression of
cancer cell survival as a means of cancer management.
The advantage of HMBME is several fold: 1) because of its
smaller size, that nevertheless retains essential chemical
functionality, HMBME can be expected to have a more
favorable solubility than curcumin while still retaining curcu-
min’s favorable biologic activities; and 2) lack of dieneone
functions in HMBME will prevent it from undergoing rapid
reductive metabolism as observed with curcumin, increasing
its bioavailability. Much preclinical work would needs to be
done before concluding the HMBME should move forward
into clinical trials for PCA; however, we believe that if efficacy
can be validated in several rodent models, it will be found that
HMBME is well tolerated with little systemic toxicity.
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